Sickle Cell Disease: Clinical Trials

419 completed, 124 recruiting, 86 terminated, 69 unknown. 207 Phase 2, 205 Not applicable, 136 Phase 1, 79 Phase 3, 26 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	207	Completed 91, Recruiting 35, Terminated 33, Active not recruiting 19, Unknown 14, Withdrawn 11, Not yet recruiting 3, Enrolling by invitation 1
Not applicable	205	Completed 116, Recruiting 36, Unknown 19, Terminated 14, Active not recruiting 8, Not yet recruiting 7, Withdrawn 4, Suspended 1
Phase 1	136	Completed 67, Recruiting 19, Terminated 16, Active not recruiting 15, Withdrawn 9, Unknown 5, Not yet recruiting 4, Enrolling by invitation 1
Phase 3	79	Completed 30, Terminated 20, Recruiting 11, Unknown 7, Active not recruiting 5, Not yet recruiting 3, Withdrawn 2, Enrolling by invitation 1
Phase 4	26	Completed 12, Terminated 4, Withdrawn 3, Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Unknown 1
Early Phase 1	14	Completed 6, Recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1

Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session - Sickle Cell Disease, Sickle Cell Anemia in Children	Not applicable	Not yet recruiting	Connecticut Children's Medical Center	30	2027-09-01	2026-04-29
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease	Phase 3	Withdrawn	Vertex Pharmaceuticals Incorporated		2027-07-31	2026-03-25
MBI for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease Mindfulness-based intervention - Chronic Pain, Sickle Cell Disease	Not applicable	Not yet recruiting	University of Illinois at Chicago	48	2027-02-01	2026-09-21
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease Minocycline, Placebo - Sickle Cell Disease, Cognitive Impairment	Phase 1	Not yet recruiting	University of Cincinnati	30	2026-12-01	2026-05-14
Virtual Reality for SCD VOC Sham 2D Headset Control, Passive Immersive 3D Virtual Reality, Active Immersive Interactive 3D Virtual Reality - Sickle Cell Disease	Not applicable	Recruiting	University of Maryland, Baltimore	50	2026-11-01	2026-10-16
Feasibility and Acceptability of Amani Amani - Sickle Cell Disease	Phase 1 / Phase 2	Not yet recruiting	Massachusetts General Hospital	40	2026-11-01	2026-08-07
Inflammatory Markers and Pain in Sickle Cell Disease Sickle Cell Disease		Not yet recruiting	Assiut University	75	2026-11-01	2026-10-08
Transcranial Photobiomodulation Treatment in Patients With Sickle Cell Disease Active Transcranial Photobiomodulation (TPBM), Sham Transcranial photobiomodulation (TPBM) - Sickle Cell Disease	Not applicable	Not yet recruiting	St. Jude Children's Research Hospital	60	2026-11-01	2026-09-10
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg) Sickle Cell Disease, Venous Thromboembolism		Not yet recruiting	Centre Hospitalier Universitaire de la Guadeloupe	60	2026-10-15	2026-10-01
Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis	Phase 4	Not yet recruiting	Assistance Publique - Hôpitaux de Paris	400	2026-10-01	2026-09-18
CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease	Early Phase 1	Not yet recruiting	Children's Hospital of Fudan University	5	2026-09-30	2026-05-15
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease	Phase 2	Recruiting	Mohsen Saidinejad	120	2026-09-10	2026-09-02
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related	Phase 4	Withdrawn	Emory University		2026-09-01	2026-10-19
Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease Iloprost, Placebo - Vaso-Occlusive Crises, Sickle Cell Disease	Phase 3	Not yet recruiting	University Hospital, Rouen	144	2026-09-01	2026-03-27
Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing Music Therapy, Standard of Care - Sickle Cell Disease	Not applicable	Recruiting	Emory University	25	2026-09-01	2026-09-10
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease	Phase 2	Recruiting	St. Jude Children's Research Hospital	45	2026-09-01	2026-07-23
Evolution of Sickle Cell Maculopathy Sickle Cell Disease, Macula Thickening		Completed	Christophe Orssaud	34	2026-09-01	2026-10-16
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia	Phase 2	Recruiting	Biossil Inc.	105	2026-08-13	2026-08-17
Universal Newborn Screening For Sickle Cell Disease In Mozambique Point-of-care testing (POCT) -Patient participants, Point-of-care testing (POCT) - Healthy control participants, Context Assessment for Community Health (COACH) survey - Sickle Cell Disease	Not applicable	Not yet recruiting	St. Jude Children's Research Hospital	6750	2026-08-01	2026-07-22
Early Life Exposures Among Children With Sickle Cell Disease Breastfeeding support group, Observation - Sickle Cell Disease, Adverse Childhood Experiences	Not applicable	Recruiting	University of Alabama at Birmingham	20	2026-08-01	2026-07-15

Showing 20 of 818. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (818)  ·  Vaso-Occlusive Crises (63)  ·  Thalassemia (46)  ·  Pain (40)  ·  beta-Thalassemia (38)  ·  Hemoglobinopathies (32)  ·  Anemia (27)  ·  Hematologic Diseases (23)  ·  Acute Chest Syndrome (21)  ·  Sickle Cell Trait (20)  ·  Neoplasms (16)  ·  Stroke (16)  ·  Agnosia (15)  ·  Hypertension, Pulmonary (15)  ·  Anemia, Diamond-Blackfan (14)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (817)  ·  Hemic and Lymphatic Diseases (817)  ·  Anemia, Hemolytic, Congenital (813)  ·  Genetic Diseases, Inborn (806)  ·  Anemia, Hemolytic (805)  ·  Hematologic Diseases (795)  ·  Anemia (791)  ·  Hemoglobinopathies (786)  ·  Pathological Conditions, Signs and Symptoms (134)  ·  Signs and Symptoms (78)  ·  Neurologic Manifestations (69)  ·  Pathologic Processes (64)  ·  Cardiovascular Diseases (63)  ·  Respiratory Tract Diseases (63)  ·  Lung Diseases (58)

Interventions

Hydroxyurea (45)  ·  Alemtuzumab (26)  ·  Cyclophosphamide (22)  ·  Sirolimus (21)  ·  fludarabine (21)  ·  voxelotor (21)  ·  fludarabine phosphate (20)  ·  Whole-Body Irradiation (17)  ·  Busulfan (15)  ·  Blood Specimen Collection (14)  ·  Mycophenolic Acid (13)  ·  Surveys and Questionnaires (13)  ·  thymoglobulin (12)  ·  Morphine (10)  ·  Antilymphocyte Serum (9)

Sponsors

St. Jude Children's Research Hospital (36)  ·  Assistance Publique - Hôpitaux de Paris (31)  ·  National Heart, Lung, and Blood Institute (NHLBI) (30)  ·  Emory University (26)  ·  Pfizer (24)  ·  Duke University (21)  ·  Children's Hospital Medical Center, Cincinnati (13)  ·  Novartis Pharmaceuticals (13)  ·  University of Illinois at Chicago (12)  ·  Vanderbilt University Medical Center (11)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (9)  ·  Washington University School of Medicine (9)  ·  Centre Hospitalier Universitaire de la Guadeloupe (8)  ·  Hospices Civils de Lyon (8)  ·  Indiana University (8)

Countries

United States (553)  ·  France (99)  ·  United Kingdom (64)  ·  Canada (40)  ·  Italy (32)  ·  Nigeria (32)  ·  Belgium (30)  ·  Lebanon (29)  ·  Egypt (28)  ·  Brazil (27)  ·  Netherlands (25)  ·  Kenya (24)  ·  Turkey (Türkiye) (24)  ·  Germany (19)  ·  Oman (18)

Top investigators

John F Tisdale, M.D. (11)  ·  Lakshmanan Krishnamurti, MD (8)  ·  Swee Lay Thein, M.D. (8)  ·  Michael R DeBaun, MD, MPH (6)  ·  Nirmish Shah, MD (6)  ·  Claudia Morris, MD (4)  ·  Jerlym Porter, PhD (4)  ·  Kenneth I Ataga, MD (4)  ·  Matthew M Hsieh, M.D. (4)  ·  Russell Ware, MD, PhD (4)

Results publications

PMID 36240296, PMID 37254256, PMID 40569673, PMID 42133908, PMID 36860093, PMID 36975201, PMID 38775255, PMID 38866240, PMID 39382077, PMID 41026975, PMID 41809202, PMID 23416852, PMID 30655275, PMID 30952488, PMID 31799940, PMID 32384147, PMID 33661274, PMID 34000072, PMID 34175041, PMID 35019238, PMID 35075288, PMID 36123234, PMID 36890729, PMID 38249565, PMID 38361924, PMID 38538687, PMID 39615812, PMID 39659429, PMID 40010689, PMID 40800810, PMID 40857358, PMID 40891510, PMID 41701977, PMID 41954645, PMID 42233421, PMID 42549972, PMID 10100293, PMID 10861320, PMID 16267411, PMID 1710777, PMID 17548550, PMID 18192510, PMID 18550258, PMID 18550886, PMID 19344390, PMID 19724055, PMID 19840322, PMID 19863539, PMID 20001619, PMID 20007560

NIH funding

2019 (6), 2023 (5), U01HL133996 (4), 2017 (3), 2025 (3), K23HL148310 (2), K23HL150232 (2), K24AT009893 (2), R01DK057778 (2), R01NS094041 (2), U01HL133964 (2), U01HL163983 (2), U10HL083721 (2), U24CA076518 (2), 1OT2HL152640-01 (1)